drugset / Trial / NCT00895947
Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu
Phase 2
Completed
200 enrolled
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Department of Health, Western Australia · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The aim of the study is to see if lozenges containing a low dose of interferon-alpha can prevent and/or reduce the severity of colds and flu. Starting about 1 month before the expected start of the winter colds and flu season in Perth, Australia, healthy volunteers will allow a lozenge containing interferon, or a lozenge containing no medicine (a placebo), to dissolve in their mouth once a day for 16 weeks. Blood tests at the start and end of treatment will determine whether interferon was able to prevent infections with cold/flu viruses. Once a week, volunteers will complete a survey about their cold/flu symptoms, medications taken, days of work missed, etc. to see if interferon was able to make their winter colds and flu less severe.
Timeline
- Start
- 2009-04
- Primary completion
- 2010-01
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | interferon alfa-2b | Protein / enzyme biologic | 150 iu | Oral |